It's not an STI and not a hygiene problem. GBS is a normal bowel bacterium that also colonizes the vagina, and about half the time it comes and goes on its own. The risk is only during birth: the newborn aspirates GBS passing through the canal or from broken waters, and a small fraction of exposed babies get a bloodstream infection, pneumonia, or meningitis in the first days of life 1.
The effect shows up at national scale. Early-onset GBS disease in the US ran at about 1.7 per 1,000 births before organized prevention; after universal screening it fell to about 0.23 per 1,000 2, 3. For a carrier who labors without antibiotics, the baby's chance of early disease is about one to two in a hundred; with antibiotics it drops to around one in a thousand. Among term babies who get sick, four to six in a hundred die 4. The numbers are small; the consequences when they land are not.
You'll experience it as one swab and one extra IV line.
The payoff is the call you never get on day two. Nothing changes for you in pregnancy or labor — the drug ends with the placenta, doesn't slow contractions, and doesn't restrict breastfeeding or skin-to-skin. What it buys is the NICU admission that doesn't happen. Pre-program, the US carried about seven thousand cases and four hundred newborn deaths a year; with screening those numbers are roughly a seventh of that 3. You never get a scoreboard telling you it worked.
The fine print — when to skip it, and what people get wrong
What people get wrong. A positive swab is not an infection or an STI. And it only covers early-onset disease (days 0 to 6); late-onset disease, now about half of all infant GBS, is untouched by the labor antibiotic 6.
The one skip. A planned cesarean before labor starts and before membranes rupture needs no antibiotic even with a positive swab; if labor or your waters come first, the standard rules resume 5.
Where it breaks. Timing, mostly: about a third of positive women deliver under four hours after the first dose, so the baby gets closer watching instead. The honest cost is that intrapartum antibiotics shift the baby's gut bacteria for months, largely recovered by breastfeeding and time 7.
- 1Verani JR, McGee L, Schrag SJ (2010). Prevention of Perinatal Group B Streptococcal Disease — Revised Guidelines from CDC, 2010. MMWR Recommendations and Reports. link
- 2Schrag SJ, Zywicki S, Farley MM, et al. (2000). Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis. New England Journal of Medicine. link
- 3Nanduri SA, Petit S, Smelser C, et al. (2019). Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015. JAMA Pediatrics. link
- 4Edmond KM, Kortsalioudaki C, Scott S, et al. (2012). Group B Streptococcal Disease in Infants Aged Younger Than 3 Months: Systematic Review and Meta-analysis. The Lancet. link
- 5ACOG (2020). Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion No. 797. Obstetrics & Gynecology. link
- 6Berardi A, Rossi C, Lugli L, et al. (2013). Group B Streptococcus Late-Onset Disease: 2003-2010. Pediatrics. link
- 7Azad MB, Konya T, Persaud RR, et al. (2016). Impact of Maternal Intrapartum Antibiotics, Method of Birth and Breastfeeding on Gut Microbiota During the First Year of Life: A Prospective Cohort Study. BJOG. link
Group B Strep in Pregnancy
Swab and intravenous penicillin G are bundled into standard prenatal and labor care under U.S. insurance; out-of-pocket cost typically nil. Penicillin G is one of the cheapest drugs in the obstetric formulary.
A 30-second swab at the 36-week visit (self-collection now widely offered) and an IV line during labor that is already routine. No dietary restrictions, no extra appointments, no postpartum extension.
Boyer–Gotoff 1986 RCT plus three decades of U.S./European population surveillance showing temporally precise ~80% EOGBS decline tracking IAP rollout (Schrag 2000; Nanduri 2019); Cochrane review confirms direction of effect though rates evidence very low (Ohlsson 2014); ACOG, AAP, CDC, SOGC, DGGG aligned on universal screening (ACOG 2020; Verani 2010).
Universal screening + intrapartum antibiotic prophylaxis (IAP) reduces early-onset GBS disease (EOGBS) in newborns by ~80–90% across U.S. surveillance (Schrag 2000; Nanduri 2019; Fairlie 2013) and ~halves it vs risk-based programs (Hasperhoven 2020). For the typical pregnant reader this is the difference between baby-and-home and a neonatal sepsis admission — a clear functional improvement on the family's first weeks even though the per-mother experience is unchanged.
Pre-guidance EOGBS killed ~400 U.S. infants annually and disabled hundreds more with meningitis-related sequelae (Nanduri 2019; Seale 2017 globally). IAP prevents most of those deaths and a meaningful share of GBS-attributable stillbirths — small additive mortality effect at the family level, scored on consequence rather than per-mother frequency since the absolute risk in any one pregnancy is low.
Avoided NICU admission, lumbar puncture, and the maternal-mental-health hit of a septic newborn account for the small positive mood score; the protection is counterfactual and probabilistic, so a trivial lift on average — but the avoided trauma is real for the affected minority.